Enveric Biosciences (STU:SLZ0) Pretax Margin %: % (As of Mar. 2026)


STU:SLZ0 Enveric Biosciences Inc STU:SLZ0
30 GF Score
Price €55.89
! 1 Warning Sign
View Full Analysis

What is Enveric Biosciences Pretax Margin %?

Enveric Biosciences STU:SLZ0 30 Pretax Margin % is % as of Mar. 2026. GuruFocus rates STU:SLZ0 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Enveric Biosciences ranks worse than 106269.82% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Enveric Biosciences's Pre-Tax Income for the three months ended in Mar. 2026 was €-1.41 Mil. Enveric Biosciences's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Enveric Biosciences's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Enveric Biosciences's Pretax Margin % or its related term are showing as below:


STU:SLZ0's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.37
* Ranked among companies with meaningful Pretax Margin % only.

Enveric Biosciences  (STU:SLZ0) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Enveric Biosciences Pretax Margin % Related Terms


Enveric Biosciences Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Enveric Biosciences's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enveric Biosciences Pretax Margin % Chart

Enveric Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Enveric Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:SLZ0 vs APVO, CNSP, ADIL: Pretax Margin % Comparison

For the Biotechnology subindustry, Enveric Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Pretax Margin % falls into.


STU:SLZ0
30GF Score
Enveric Biosciences Inc STU:SLZ0
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enveric Biosciences Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Enveric Biosciences's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-7.491/0
= %

Enveric Biosciences's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.413/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Enveric Biosciences (STU:SLZ0) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Enveric Biosciences and its competitors. According to the industry distribution chart, Enveric Biosciences ranks #999999 out of 941 companies in the Biotechnology industry.
Is Enveric Biosciences' Pretax Margin % too high?
Enveric Biosciences' current Pretax Margin % is %. Based on the distribution chart, Enveric Biosciences ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' Pretax Margin % compare to APVO and CNSP?
According to the Biotechnology industry distribution chart, Enveric Biosciences ranks #999999 out of 941 companies for Pretax Margin %. This places Enveric Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Enveric Biosciences and its competitors. Enveric Biosciences's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (STU:SLZ0) has a current Pretax Margin % of %. The current Pretax Margin % is %. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Enveric Biosciences (STU:SLZ0), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enveric Biosciences Business Description

Other Exchanges ENVB:USA
Address 245 First Street, 18th Floor, Riverview II, Cambridge, MA, USA, 02142
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score

Get the complete analysis for STU:SLZ0

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.89
Price